Pfizer Inc. reports that the US Food and Drug Administration (FDA) has granted Fast Track designation to the company's investigational Clostridium difficile (C. difficile) vaccine candidate (PF-06425090). The vaccine, designed to prevent a difficult-to-treat healthcare associated infection, is currently in Phase II clinical development.

The FDA's Fast Track approach is a process designed to facilitate the development and expedite the review of new drugs and vaccines intended to treat or prevent serious conditions and address an unmet medical need.

Source: Pfizer